Holen Sie sich die Stockscreener-App
1.32
0.00%
0.00
Schlusskurs vom Vortag:
$1.32
Offen:
$1.3
24-Stunden-Volumen:
119.85K
Relative Volume:
0.40
Marktkapitalisierung:
$56.61M
Einnahmen:
$51.13M
Nettoeinkommen (Verlust:
$-93.80M
KGV:
-0.5919
EPS:
-2.23
Netto-Cashflow:
$-129.10M
1W Leistung:
-0.75%
1M Leistung:
-3.65%
6M Leistung:
-53.02%
1J Leistung:
-60.00%
1-Tages-Spanne:
$1.29
$1.34
1-Wochen-Bereich:
$1.29
$1.39
52-Wochen-Spanne:
$0.89
$4.29
Repare Therapeutics Inc Stock (RPTX) Company Profile
Firmenname
Repare Therapeutics Inc
Sektor
Branche
Telefon
(857) 412-7018
Adresse
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Vergleichen Sie RPTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.32 | 57.05M | 51.13M | -93.80M | -129.10M | -2.23 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-09 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-12 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-17 | Fortgesetzt | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Stifel | Buy |
| 2021-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2020-10-28 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-14 | Eingeleitet | Cowen | Outperform |
| 2020-07-14 | Eingeleitet | Goldman | Neutral |
| 2020-07-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Repare Therapeutics Inc Aktie (RPTX) Neueste Nachrichten
Repare Therapeutics Inc. (NASDAQ:RPTX) is MPM Asset Management LLC's 6th Largest Position - MarketBeat
MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News
RPTX Advances Pipeline with Strategic Partnership | RPTX Stock N - GuruFocus
Tower Research Capital LLC TRC Purchases 23,127 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Provides Business - citybiz
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results - ADVFN
Repare Therapeutics Provides Business and Clinical Update and Re - GuruFocus
Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates - TipRanks
Repare Therapeutics Inc’s Market Journey: Closing Weak at 1.33, Down -5.00 - DWinneX
Marshall Wace LLP Decreases Stake in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
JPMorgan Chase & Co. Boosts Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Renaissance Technologies LLC Has $455,000 Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News
Repare Therapeutics Inc. Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - marketscreener.com
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News
Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus
Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com
Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX
Repare Therapeutics Inc (RPTX) Stock: Uncovering 52-Week Market Trends - investchronicle.com
B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating - marketscreener.com
Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics - Investing.com UK
Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock By Investing.com - Investing.com India
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga
Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga
Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock - Investing.com
Repare Therapeutics Stock Hits 52-Week Low at $0.98 Amid Market Challenges - Investing.com
Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals
Repare Therapeutics details discovery of PLK4 inhibitor RP-1664 - BioWorld MedTech
Repare Therapeutics Appoints Steve Forte CEO - citybiz
Repare Therapeutics appoints CFO as new CEO - MSN
Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener
Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks
Repare Therapeutics Names Forte as President, CEO - MarketWatch
Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks
Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Repare Therapeutics Announces Leadership Transitions - Business Wire
Finanzdaten der Repare Therapeutics Inc-Aktie (RPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):